These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38944863)

  • 61. Fecal calprotectin-guided dosing of mesalamine in ulcerative colitis: concept proved but more data needed.
    Vande Casteele N; Sandborn WJ
    Clin Gastroenterol Hepatol; 2014 Nov; 12(11):1894-6. PubMed ID: 24951843
    [No Abstract]   [Full Text] [Related]  

  • 62. Accuracy of Rapid Fecal Calprotectin Test in Monitoring Inflammatory Bowel Diseases Under Treatment with TNFα Antagonists.
    Tursi A; Elisei W; Picchio M; Giorgetti G; Brandimarte G
    Dig Dis Sci; 2015 May; 60(5):1406-13. PubMed ID: 25445163
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Concept for a rapid point-of-care calprotectin diagnostic test for diagnosis and disease activity monitoring in patients with inflammatory bowel disease: expert clinical opinion.
    Rogler G; Aldeguer X; Kruis W; Lasson A; Mittmann U; Nally K; Peyrin-Biroulet L; Schoepfer A; Vatn M; Vavricka S; Logan R
    J Crohns Colitis; 2013 Sep; 7(8):670-7. PubMed ID: 23517932
    [No Abstract]   [Full Text] [Related]  

  • 64. Systematic Review with Meta-Analysis: Fecal Calprotectin as a Surrogate Marker for Predicting Relapse in Adults with Ulcerative Colitis.
    Li J; Zhao X; Li X; Lu M; Zhang H
    Mediators Inflamm; 2019; 2019():2136501. PubMed ID: 31275056
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Role of faecal calprotectin as a predictor of endoscopic activity in paediatric patients with ulcerative colitis.
    Shentova R; Baycheva M; Hadjiiski P; Kofinova D; Yaneva P
    Gastroenterol Hepatol; 2020 Jan; 43(1):57-61. PubMed ID: 31733888
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Immunoanalytical characteristics of fecal calprotectin.
    Desbène C; Gaillard O; Kapel N
    Ann Biol Clin (Paris); 2016 Dec; 74(6):725-734. PubMed ID: 27848924
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Fecal chromogranins and secretogranins are increased in patients with ulcerative colitis but are not associated with disease activity.
    Strid H; Simrén M; Lasson A; Isaksson S; Stridsberg M; Öhman L
    J Crohns Colitis; 2013 Dec; 7(12):e615-22. PubMed ID: 23694857
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Histologic Evaluation Using the Robarts Histopathology Index in Patients With Ulcerative Colitis in Deep Remission and the Association of Histologic Remission With Risk of Relapse.
    Park J; Kang SJ; Yoon H; Park J; Oh HJ; Na HY; Lee HS; Shin CM; Park YS; Kim N; Lee DH
    Inflamm Bowel Dis; 2022 Nov; 28(11):1709-1716. PubMed ID: 35016209
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Prediction of endoscopic disease activity in ulcerative colitis by two different assays for fecal calprotectin.
    Kristensen V; Klepp P; Cvancarova M; Røseth A; Skar V; Moum B
    J Crohns Colitis; 2015 Feb; 9(2):164-9. PubMed ID: 25518057
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Platelet-to-lymphocyte percentage ratio for assessing disease activity and predicting therapeutic outcomes in ulcerative colitis.
    Zheng J; Wang Y; Li L; Chen M; Chen R; Zhang S
    Int Immunopharmacol; 2024 Aug; 137():112506. PubMed ID: 38914032
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Fecal Calprotectin.
    Ayling RM; Kok K
    Adv Clin Chem; 2018; 87():161-190. PubMed ID: 30342711
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Rapid fecal calprotectin correlates with clinical and endoscopic severity of inflammatory bowel diseases.
    Tursi A; Elisei W; Giorgetti G; Picchio M; Brandimarte G
    Scand J Gastroenterol; 2013 Nov; 48(11):1359-60. PubMed ID: 23971760
    [No Abstract]   [Full Text] [Related]  

  • 73. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.
    Guidi L; Marzo M; Andrisani G; Felice C; Pugliese D; Mocci G; Nardone O; De Vitis I; Papa A; Rapaccini G; Forni F; Armuzzi A
    Dig Liver Dis; 2014 Nov; 46(11):974-9. PubMed ID: 25096964
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Engineered calprotectin-sensing probiotics for IBD surveillance in humans.
    Xia JY; Hepler C; Tran P; Waldeck NJ; Bass J; Prindle A
    Proc Natl Acad Sci U S A; 2023 Aug; 120(32):e2221121120. PubMed ID: 37523538
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical factors to predict flare-up in patients with inflammatory bowel disease during international air travel: A prospective study.
    Park J; Yoon H; Shin CM; Park YS; Kim N; Lee DH
    PLoS One; 2022; 17(1):e0262571. PubMed ID: 35061808
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis.
    Lee SH; Kim MJ; Chang K; Song EM; Hwang SW; Park SH; Yang DH; Kim KJ; Byeon JS; Myung SJ; Yang SK; Ye BD
    BMC Gastroenterol; 2017 Oct; 17(1):110. PubMed ID: 29061121
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Fecal calprotectin and ulcerative colitis endoscopic activity index as indicators of mucosal healing in ulcerative colitis.
    Taghvaei T; Maleki I; Nagshvar F; Fakheri H; Hosseini V; Valizadeh SM; Neishaboori H
    Intern Emerg Med; 2015 Apr; 10(3):321-8. PubMed ID: 25366383
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.
    Zittan E; Kelly OB; Kirsch R; Milgrom R; Burns J; Nguyen GC; Croitoru K; Van Assche G; Silverberg MS; Steinhart AH
    Inflamm Bowel Dis; 2016 Mar; 22(3):623-30. PubMed ID: 26829408
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis.
    Ho GT; Lee HM; Brydon G; Ting T; Hare N; Drummond H; Shand AG; Bartolo DC; Wilson RG; Dunlop MG; Arnott ID; Satsangi J
    Am J Gastroenterol; 2009 Mar; 104(3):673-8. PubMed ID: 19262524
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease.
    Zhulina Y; Cao Y; Amcoff K; Carlson M; Tysk C; Halfvarson J
    Aliment Pharmacol Ther; 2016 Sep; 44(5):495-504. PubMed ID: 27402063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.